Online citations, reference lists, and bibliographies.
← Back to Search

PLGA Nanoparticles For Peroral Delivery: How Important Is Pancreatic Digestion And Can We Control It?

Anika Mante, M. Heider, Christin Zlomke, K. Mäder
Published 2016 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Biodegradable nanoparticles made of Poly(lactide-co-glycolide) are increasingly proposed for the improvement of oral drug absorption, but also as carriers for the treatment of colonic diseases. Unfortunately, our knowledge of the digestibility of PLGA-NPs is rather limited. Therefore, we investigated the impact of pancreatin on the digestibility of PLGA-NPs stabilized with different emulsifiers. The pancreatin induced degradation was monitored by the pH-stat method and an enzymatic l-lactic acid assay. A high digestibility was found for poloxamer 188 and polysorbate 80 stabilized PLGA-NPs. The digestion could be blocked by Orlistat, indicating a major role of pancreatic lipase. PLGA-NPs stabilized with Poly(vinyl alcohol) (=PVA) were not digested at comparable surfactant concentrations (0.6%). However, PLGA-NPs stabilized with very low amounts of PVA (0.1%) were digestible. In conclusion, PLGA-NPs are substrates for the pancreatic lipase. The digestibility can be enhanced or blocked by the proper selection of the surfactant composition and concentration.
This paper references
C
W. J. Mayer (2013)
V
D. R. Kalaria (2009)
10.1016/j.jconrel.2014.05.046
Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis.
B. Moulari (2014)
10.1016/S0142-9612(02)00377-0
Enzymatic degradation behavior and mechanism of poly(lactide-co-glycolide) foams by trypsin.
Q. Cai (2003)
10.1016/j.ijpharm.2011.12.038
Antacid co-encapsulated polyester nanoparticles for peroral delivery of insulin: development, pharmacokinetics, biodistribution and pharmacodynamics.
G. Sharma (2013)
A
C. Lautenschläger (2013)
Y
K. Tahara (2011)
10.1016/j.biomaterials.2010.09.034
Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease.
Kohei Tahara (2011)
10.1007/S10856-007-3292-2
In vitro and in vivo degradation of poly(l-lactide-co-glycolide) films and scaffolds
E. Pamuła (2008)
10.1021/mp400311j
Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity.
A. Jain (2013)
10.1021/mp400358z
Orally administered nanocurcumin to attenuate morphine tolerance: comparison between negatively charged PLGA and partially and fully PEGylated nanoparticles.
Hao Shen (2013)
10.1016/j.msec.2013.10.038
Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design.
U. Shah (2014)
E
S. H. Bakhru (2013)
10.1016/j.ijpharm.2011.05.049
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review.
S. Fredenberg (2011)
10.1198/jasa.2005.s47
Optimization
R. Steele (2005)
10.1097/MAO.0000000000000434
Controlled Release Dexamethasone Implants in the Round Window Niche for Salvage Treatment of Idiopathic Sudden Sensorineural Hearing Loss
S. Plontke (2014)
10.1007/s11095-008-9763-4
Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats
D. R. Kalaria (2008)
10.3109/10611869808996837
Peroral administration of 14C-poly(D,L-lactic acid) nanoparticles coated with human serum albumin or polyvinyl alcohol to guinea pigs.
F. Landry (1998)
V
D. K. Sahana (2008)
A
S. Fredenberg (2011)
10.1021/la301820w
Effects of emulsifier charge and concentration on pancreatic lipolysis: 2. Interplay of emulsifiers and biles.
Zahari Vinarov (2012)
N
C. N. Grama (2013)
10.1177/146642407409400210
(b)
Miss A.O. Penney (1974)
10.2307/j.ctvrnfqk1.10
? ? ? ? f ? ? ? ? ?
A. ADoefaa (2003)
10.1016/0142-9612(96)86742-1
Degradation of poly(D,L-lactic acid) nanoparticles coated with albumin in model digestive fluids (USP XXII).
F. Landry (1996)
A
A. Beloqui (2014)
A
Y. Meissner (2006)
10.3390/POLYM3031377
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.
Hirenkumar K. Makadia (2011)
10.1016/j.ejps.2010.07.005
Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes.
Anne Christiansen (2010)
10.1021/BM010048K
Enzymatic hydrolysis of poly(lactide)s: effects of molecular weight, L-lactide content, and enantiomeric and diastereoisomeric polymer blending.
H. Tsuji (2001)
10.1002/JPS.21158
PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug.
D. Sahana (2008)
10.1016/S0141-3910(99)00091-9
Enzymatic degradation of stereocopolymers derived from L-, DL- and meso-lactides
S. Li (2000)
In vitro and in vivo degradation of poly(l-lactide-coglycolide) films and scaffolds
E. Pamula (2008)
10.1016/j.jconrel.2014.03.039
Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
H. Ali (2014)
A
M. Garinot (2007)
Y
H. Shen (2013)
10.1177/001452469000101110
"J."
G.G. Stokes (1890)
R
N. Reix (2012)
K
U. Shah (2014)
10.1208/s12248-014-9564-0
Novel Lansoprazole-Loaded Nanoparticles for the Treatment of Gastric Acid Secretion-Related Ulcers: In Vitro and In Vivo Pharmacokinetic Pharmacodynamic Evaluation
M. Alai (2014)
10.1016/S0169-409X(97)00056-2
Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions.
Maria Comaru-Schally A (1997)
10.1016/0142-9612(96)89664-5
Non-invasive in vivo characterization of release processes in biodegradable polymers by low-frequency electron paramagnetic resonance spectroscopy.
K. Mader (1996)
10.1016/j.ijpharm.2014.07.009
pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
A. Beloqui (2014)
10.1016/J.JCONREL.2007.01.016
Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
G. Mittal (2007)
10.1016/S0168-3659(96)01526-X
Release of the fluorescent marker Prodan® from poly(D,L-lactic acid) nanoparticles coated with albumin or polyvinyl alcohol in model digestive fluids (USP XXII)
F. J. Landry (1997)
10.1016/J.JCONREL.2007.04.021
PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination.
M. Garinot (2007)
10.1038/eye.2013.79
Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion
W. Mayer (2013)
V
G. Mittal (2007)
10.1161/HC0202.101988
In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits
Y. Jiao (2002)
10.1016/j.addr.2013.04.006
Oral delivery of proteins by biodegradable nanoparticles.
S. Bakhru (2013)
10.1016/S0927-7765(99)00157-5
The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration.
Tobío (2000)
10.1016/j.ijpharm.2012.08.024
In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles.
N. Reix (2012)
10.1371/journal.pone.0078217
Efficacy of Biodegradable Curcumin Nanoparticles in Delaying Cataract in Diabetic Rat Model
C. Grama (2013)
10.1002/jps.23087
Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation.
G. Kumar (2012)
A
B. Moulari (2014)
K
S. K. Plontke (2014)
10.1016/j.jconrel.2012.01.043
PLGA-based nanoparticles: an overview of biomedical applications.
F. Danhier (2012)
10.1016/j.addr.2012.09.004
Biodegradation and biocompatibility of PLA and PLGA microspheres.
Shive (1997)
10.1016/j.biomaterials.2014.07.026
The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium.
F. Araújo (2014)
10.1016/j.ejpb.2015.05.018
Mechanistic analysis of PLGA/HPMC-based in-situ forming implants for periodontitis treatment.
M. P. Do (2015)
10.1016/J.IJPHARM.2006.01.032
Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery.
Y. Meissner (2006)
10.1016/j.ejpb.2013.09.016
PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
Christian Lautenschläger (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar